| dc.contributor.author |
Murugesan, Sankaranarayanan |
|
| dc.date.accessioned |
2023-12-11T10:42:20Z |
|
| dc.date.available |
2023-12-11T10:42:20Z |
|
| dc.date.issued |
2021-04 |
|
| dc.identifier.uri |
https://www.tandfonline.com/doi/full/10.1080/17460441.2021.1916464 |
|
| dc.identifier.uri |
http://dspace.bits-pilani.ac.in:8080/xmlui/handle/123456789/13344 |
|
| dc.description.abstract |
Cancer is a dreadful disorder that is emerging as one of the leading causes of mortality across the globe. The complex tumor environment, supplemented with drawbacks of the existing drugs, has made it a global health concern. The Tetrahydroisoquinoline (THIQ) ring holds an important position in medicinal chemistry due to its wide range of pharmacological properties. Several THIQ based natural products have been previously explored for their antitumor properties, making it a vital scaffold for anticancer drug design. |
en_US |
| dc.language.iso |
en |
en_US |
| dc.publisher |
Taylor & Francis |
en_US |
| dc.subject |
Pharmacy |
en_US |
| dc.subject |
Tumor |
en_US |
| dc.subject |
Benzo piperidine |
en_US |
| dc.subject |
3, 4-dihydro-1H-isoquinoline |
en_US |
| dc.subject |
1, 2, 3, 4-tetrahydro-2-azanaphthalene |
en_US |
| dc.subject |
Synthesis |
en_US |
| dc.subject |
Epigenetics |
en_US |
| dc.title |
1,2,3,4-Tetrahydroisoquinoline (THIQ) as privileged scaffold for anticancer de novo drug design |
en_US |
| dc.type |
Article |
en_US |